Changing therapeutic behaviour after FOURIER

10' education - Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

PCSK9 Expert Opinions Prof. Wolfgang Koenig describes the results of FOURIER and SPIRE. He expects that PCSK9 inhibitors will be drugs of great value in the future, especially for patients with FH and statin intolerance.

Video navigation menu

Are the results of FOURIER a surprise? 01:13
Did the SPIRE results resemble those of FOURIER? 02:16
FOURIER will change the therapeutic behaviour, probably on a different level in different countries 03:03
The German situation: 3 different indications expected to benefit most from PCSK9 inhibition 03:39
Challenge: A better definition of the group of patients not reaching target LDL-c to change practice in this group 04:38
Aggressive lipid lowering with PCSK9 inhibitors translates into clinically relevant reductions of various endpoints 06:13

Educational information

This educational video is part of a series of PCSK9 Expert Opinions that are aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice

The educational content reflects the personal opinion of the experts and is recorded as an independent educational service by PACE-CME

Disclosures

Prof. Wolfgang Koenig - German Heart Center, Munich, Germany

Funding

Funding was provided by an unrestricted educational grant from Amgen

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.